title: FXR Agonists: From Bench to Bedside, a Guide for Clinicians.
authors.affiliation: NIDDK/Liver Disease Branch, National Institute of Health, 10 Center Drive, CRC Bldg. 10, RM 4-5722, Bethesda, MD, 20892, USA.
authors.forename: Ahmad Samer
authors.initials: AS
authors.lastname: Alawad
authors.affiliation: Division of Hepatology, University of Miami Miller School of Medicine, 1500 NW 12th Avenue, Suite 1101, Miami, FL, 33136, USA. clevy@med.miami.edu.
authors.forename: Cynthia
authors.initials: C
authors.lastname: Levy
mesh_terms: D000818:Animals; D001381:Azepines; D002635:Chenodeoxycholic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D002756:Cholagogues and Choleretics / Q000627:therapeutic use*; D002779:Cholestasis / Q000188:drug therapy; D004353:Drug Evaluation, Preclinical; D005765:Gastrointestinal Agents; D019693:Hepatitis, Autoimmune / Q000188:drug therapy; D006801:Humans; D006975:Hypertension, Portal / Q000188:drug therapy; D007211:Indoles; D007555:Isoxazoles; D008104:Liver Cirrhosis, Alcoholic / Q000188:drug therapy; D008105:Liver Cirrhosis, Biliary / Q000188:drug therapy; D008107:Liver Diseases / Q000188:drug therapy*; D024821:Metabolic Syndrome / Q000188:drug therapy*; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists*; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use; D000099150:Receptor, Farnesoid X-Activated
chemical_list: D001381:Azepines; D002635:Chenodeoxycholic Acid; D002756:Cholagogues and Choleretics; D005765:Gastrointestinal Agents; D007211:Indoles; D007555:Isoxazoles; D018160:Receptors, Cytoplasmic and Nuclear; D014580:Ursodeoxycholic Acid; D000099150:Receptor, Farnesoid X-Activated; C540004:WAY-362450; C464660:obeticholic acid; C412815:GW 4064